Quote:

---

Merck and Pfizer were not immune modulators but that Tollovir was both

---

Someone asked me about Tolliver on stocktwits. my initial reply -

Quote:

---

With 3CL protease inhibitors you've either got it right and it binds the RNA effectively or it's useless. PIs have a similar method of action to my proposed PI3K/AKT/mTORc1 downregulation blocking the capsid from activating cleavage. But leronlimab would not be as effective at it as a PI.

Whether Todos has an effective drug is still up in the air. It was a study not a trial and done haphazardly. No blinding, no randomization and the selection criteria highly favored Tollovir over controls. Tollovir patients had a mean of 13.3 days hospitalized vs. 17.4 for control. With a peak in days of 19 days for Tollovir vs. 41 for control. The longer you're in the hospital the more likely you are to be put on vent or ECMO and the more likely you are to die. That study was obscenely bad but it's often seen from Israel bio companies.

Personally I would stay away from it until Phase 2 trial results. If you must have some buy only enough that if you lose it, it won't cause to much pain.

---

Then dug a little deeper -

Quote:

---

Why did they do a study rather than a clinical trial? Simply to sell more of their supplement if they really wanted to prove it they'd do a trial. But the active ingredient (Lithospermum Erythrochizon) can be bought cheaper elsewhere. Lithospermum Erythrochizon can have some effect on immumodulation but I have found no other scientific claims to it's ability as a protease inhibitor. There's not even a mechanism of action on how it would work as such. What it looks like is false claims and a scam.

---

So that article writer could have figured out the same in a short amount of time. But he didn't because it's a manipulative piece. Trust no one's opinion about stocks until they've earned your trust and even then do your own due diligence.